TrialsgrambetaRCTs are beautiful

TORCH

2007

Towards a Revolution in COPD Health

In 6,112 patients with moderate-to-severe COPD, salmeterol-fluticasone reduced 3-year all-cause mortality only borderline-significantly compared with placebo.

Result

Efficacy: All-cause mortality at 3 yearsHR 0.825 · P = 0.052

Below 1 favours salmeterol-fluticasone, above 1 favours placebo.

Event rates
Absolute difference
2.6 points

The absolute difference is derived from the event rates.

Also reported: Exacerbations reduced 25%. Pneumonia 19.6% vs 12.3%.

Original publication
Subtopic
ICS/LABA
Design
Multicentre RCT
Relevance
Important: one of several pillars.
Source
Calverley PMA, et al. N Engl J Med. 2007;356(8):775-789.doi 10.1056/NEJMoa063070

Discussion & critique

First large mortality trial in COPD; established LABA/ICS for exacerbation reduction and surfaced the ICS-pneumonia signal that persists in later trials.

Discussed in podcasts